---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations. 1 evidence topic quoted from 0 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations

<a id="terms-and-abbreviations"></a>

## Terms and Abbreviations

<a id="topic-terms-and-abbreviations-1"></a>

| Abbreviation | Term |
| --- | --- |
| 14C-IVA337 | Carbon-14-labeled IVA337 (lanifibranor) |
| 1H-MRS, ¹H-MRS | Proton magnetic resonance spectroscopy |
| A3, A4 | SAF activity score of 3, of 4 |
| AA | African American |
| AASLD | American Association for the Study of Liver Diseases |
| ADA | American Diabetes Association |
| Adipo-IR | Adipose tissue insulin resistance index |
| ADP | Adiponectin |
| AE, AEs | Adverse event |
| AESIs | Adverse events of special interest |
| AFwC | Advanced fibrosis (stage 3 to 4) with additional cardiovascular, renal, and metabolic comorbidities |
| AGA | American Gastroenterological Association |
| AHA | American Heart Association |
| AHFS | American Hospital Formulary Service |
| aHR | Adjusted hazard ratio |
| AI/AN | American Indian/Alaska Native |
| ALD | Alcohol-associated liver disease; alcohol-related liver disease |
| ALP | Alkaline phosphatase |
| ALT | Alanine aminotransferase |
| AMD | Adjusted mean difference versus placebo |
| ANCOVA | Analysis of covariance |
| API | Asian/Pacific Islander |
| APO-A, APO-B, APO-C3 | Apolipoprotein A, apolipoprotein B, apolipoprotein C3 |
| AST | Aspartate aminotransferase |
| ATE | Active treatment extension |
| AUC | Area under the curve |
| AUC0-τ | Area under the curve from time zero to the last measurable concentration |
| BCRP | Breast cancer resistance protein |
| BCS | Biopharmaceutics Classification System |
| BID | Twice daily |
| BIMs | Budget impact models |
| BL | Baseline |
| BMI | Body mass index |
| BMS | Bristol Myers Squibb |
| BNP | Brain natriuretic peptide |
| BP | Blood pressure |
| BSA, BSAs | Body surface area; share subscription warrants (bons de souscription d'actions) |
| BSEP | Bile salt export pump |
| CA | California |
| CAP | Controlled attenuation parameter |
| CAS | Chemical Abstracts Service |
| CC | Compensated cirrhosis |
| CD34 | Cluster of differentiation 34 (marker of liver sinusoidal endothelial cell capillarisation) |
| CDAA-HFD | Choline-deficient, L-amino acid-defined, high-fat diet |
| CDC | Centers for Disease Control and Prevention |
| CDM | Clinformatics Data Mart (Optum) |
| CHB | Chronic hepatitis B |
| CHC | Chronic hepatitis C |
| CI | Confidence interval |
| CKD | Chronic kidney disease |
| CLDQ | Chronic Liver Disease Questionnaire |
| CLDQ-MASH | Chronic Liver Disease Questionnaire, metabolic dysfunction-associated steatohepatitis version |
| CLDQ-NAFLD | Chronic Liver Disease Questionnaire, Non-Alcoholic Fatty Liver Disease version |
| CLDQ-NASH | Chronic Liver Disease Questionnaire, nonalcoholic steatohepatitis version |
| CMH | Cardiometabolic health |
| CO2 | Carbon dioxide |
| COVID-19 | Coronavirus disease 2019 |
| CrI | Credible interval |
| CRN | Clinical Research Network |
| CRN-B | Clinical Research Network hepatocyte ballooning score |
| CRN-F | Clinical Research Network fibrosis score |
| CRN-I | Clinical Research Network lobular inflammation score |
| CRN-S | Clinical Research Network steatosis score |
| CRP | C-reactive protein |
| CS | Clinically significant |
| CT | Computed tomography |
| cT1 | Corrected T1 (iron-corrected T1 mapping by multiparametric MRI) |
| CTTQ | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| CV | Cardiovascular |
| CVD | Cardiovascular disease |
| CVRM | Cardiovascular, renal, and metabolic |
| CYP, CYP450 | Cytochrome P450 |
| CYP2B6 | Cytochrome P450 2B6 |
| CYP2C19 | Cytochrome P450 2C19 |
| CYP2C8 | Cytochrome P450 2C8 |
| CYP2C9 | Cytochrome P450 2C9 |
| CYP3A4 | Cytochrome P450 3A4 |
| DALYs | Disability-adjusted life years |
| dB/m | Decibels per meter |
| DBP | Diastolic blood pressure |
| DBPC | Double-blind placebo-controlled |
| DCC | Decompensated cirrhosis |
| DCE | Discrete choice experiment |
| DEAN | Dapagliflozin Efficacy and Action in NASH (phase 3 trial of dapagliflozin) |
| DILI | Drug-induced liver injury |
| DMC | Data Monitoring Committee |
| DNL | De novo lipogenesis |
| DOA | Duration of approval |
| DPP-4, DPP-IV | Dipeptidyl peptidase 4 |
| DPP-IVi | Dipeptidyl peptidase 4 inhibitor |
| E167K | Glutamate-to-lysine substitution at position 167 (TM6SF2 variant) |
| EASD | European Association for the Study of Diabetes |
| EASL | European Association for the Study of the Liver |
| EASO | European Association for the Study of Obesity |
| EC50 | 50% effective concentration |
| ECG | Electrocardiogram |
| eCRF | Electronic case report form |
| EEA | European Economic Area |
| EFnoC | Early fibrosis (stage 0 to 2) without additional cardiovascular, renal, and metabolic comorbidities |
| EFwC | Early fibrosis (stage 0 to 2) with additional cardiovascular, renal, and metabolic comorbidities |
| EFX | Efruxifermin |
| eGFR | Estimated glomerular filtration rate |
| EHR | Electronic health record |
| ELF | Enhanced Liver Fibrosis (test or score) |
| ELTR | European Liver Transplant Registry |
| EMA | European Medicines Agency |
| Emax | Maximal effect |
| EoS | End of study |
| EOT | End of treatment |
| EQ-5D | EuroQol 5-Dimension |
| EQ-5D-5L | EuroQol 5-Dimension 5-Level |
| ER | Endoplasmic reticulum; emergency room |
| ETNB | 89bio, Inc. Nasdaq ticker symbol |
| EU | European Union |
| EU5 | France, Germany, Italy, Spain, and the United Kingdom |
| EudraCT | European Union Drug Regulating Authorities Clinical Trials Database |
| evLYs | Equal value life years |
| F0 | Fibrosis stage 0 (no fibrosis) |
| F1 | Fibrosis stage 1 |
| F1B | Fibrosis stage 1B |
| F2 | Fibrosis stage 2 |
| F3 | Fibrosis stage 3 (bridging fibrosis) |
| F4 | Fibrosis stage 4 (cirrhosis) |
| FA | Fatty acid |
| FAS | Full analysis set |
| FAST | FibroScan-AST score |
| FDA | Food and Drug Administration |
| FFS | Flinders Fatigue Scale |
| FG | Fasting glucose |
| FGF21 | Fibroblast growth factor 21 |
| FIB-4, FIB4, Fib4 | Fibrosis-4 index |
| FIL | Fasting insulin levels |
| FL | Florida |
| FPG | Fasting plasma glucose |
| GAIN | Global Assessment of the Impact of NASH (study) |
| GCEA | Generalized cost-effectiveness analysis |
| GFR | Glomerular filtration rate |
| GGT | Gamma-glutamyl transferase |
| GI | Gastrointestinal |
| GIP | Glucose-dependent insulinotropic polypeptide |
| GLP-1 | Glucagon-like peptide-1 |
| GLP-1 RA, GLP-1RA, GLP-1-RA, GLP1RA | Glucagon-like peptide-1 receptor agonist |
| GmbH | Gesellschaft mit beschränkter Haftung (limited liability company) |
| GMI | Glucose management indicator |
| GSD | Glycemic Status Assessment for Patients With Diabetes (HEDIS measure) |
| GSK | GSK plc |
| GT | Ground truth |
| GW501516 | Reference PPARδ agonist compound |
| HbA1c, A1c, A1C | Hemoglobin A1c |
| HBPB | Health Benefit Price Benchmark |
| HCC | Hepatocellular carcinoma |
| HCP, HCPs | Health care professional; health care provider |
| HCSC | Health Care Service Corporation |
| HDL | High-density lipoprotein |
| HDL-C | High-density lipoprotein cholesterol |
| HDPE | High-density polyethylene |
| HEDIS | Healthcare Effectiveness Data and Information Set |
| HGP | Hepatic glucose production |
| hHSC | Human hepatic stellate cell |
| HMW | High-molecular-weight |
| HOMA-IR | Homeostatic Model Assessment of Insulin Resistance |
| hPPARs | Human peroxisome proliferator-activated receptors |
| HR | Hazard ratio |
| HRQL, HRQoL | Health-related quality of life |
| HRU | Health care resource utilization |
| hs-CRP | High-sensitivity C-reactive protein |
| HSC | Hepatic stellate cell |
| HSD17B13 | Hydroxysteroid 17-beta dehydrogenase 13 |
| HTN | Hypertension |
| HTS | High throughput screening |
| I148M | Isoleucine-to-methionine substitution at position 148 (PNPLA3 variant) |
| IA | Interim analysis |
| IAS | Interim Analysis Set |
| IC50 | Half-maximal inhibitory concentration |
| ICER, ICERs | Incremental cost-effectiveness ratio; Institute for Clinical and Economic Review |
| ICF | Informed consent form |
| IHTG | Intrahepatic triglycerides |
| II, IM, MM | PNPLA3 rs738409 genotypes (homozygous isoleucine, heterozygous isoleucine/methionine, homozygous methionine) |
| ILIs | Intensive lifestyle interventions |
| IMP | Investigational Medicinal Product |
| IMS | Image management system |
| IND | Investigational new drug (application) |
| INN | International Nonproprietary Name |
| INR | International Normalized Ratio |
| IQR | Interquartile range |
| IR | Insulin resistance |
| IRB | Institutional Review Board |
| IS | Insulin sensitivity |
| ISHAK-F | Modified Ishak fibrosis score |
| ITT | Intention-to-treat |
| IU | International units |
| IV1197347, IV1197736, IV1537661 | Codes for the three major human metabolites of lanifibranor (benzothiazole ring-opened derivative, acyl glucuronide, and monohydroxylated metabolite, respectively) |
| IVA337, IVA 337 | Development code for lanifibranor |
| Ki | Inhibition constant |
| kPa | Kilopascal |
| KSA | Kingdom of Saudi Arabia |
| L | Lanifibranor (LEGEND treatment arm) |
| L+E | Lanifibranor with empagliflozin (LEGEND treatment arm) |
| LBAS | Liver biopsy analysis set |
| LBM | Lean body mass |
| LDL | Low-density lipoprotein |
| LDL-C | Low-density lipoprotein cholesterol |
| LITMUS | Liver Investigation: Testing Marker Utility in Steatohepatitis (consortium) |
| LoE | Level of evidence |
| LS | Least squares; liver stiffness; intensive lifestyle intervention |
| LSE | London Stock Exchange |
| LSEC | Liver sinusoidal endothelial cell |
| LSM, LSMs | Liver stiffness measurement |
| LT | Liver transplantation |
| LVEF | Left ventricular ejection fraction |
| M30, M65 | Cytokeratin 18 fragments (M30, apoptosis marker; M65, total fragment) |
| MA | Massachusetts |
| MACE | Major adverse cardiovascular events |
| MAD | Multiple ascending doses |
| MALF | Moderate-to-advanced liver fibrosis |
| MALO | Major adverse liver outcomes |
| MASH | Metabolic dysfunction-associated steatohepatitis |
| MASLD | Metabolic dysfunction-associated steatotic liver disease |
| MAST | MRI-AST score (MRI-PDFF, MRE, and AST) |
| MCS | Mental component summary |
| MDR1 | Multidrug resistance protein 1 |
| MDRD | Modification of Diet in Renal Disease |
| MedDRA | Medical Dictionary for Regulatory Activities |
| MEFIB | MRE combined with FIB-4 |
| MetALD | MASLD with increased alcohol intake (metabolic dysfunction and alcohol-associated liver disease) |
| MH | Mantel-Haenszel |
| mmHg | Millimeters of mercury |
| MMP-2 | Matrix metalloproteinase 2 |
| MMRM | Mixed model for repeated measures |
| MRE | Magnetic resonance elastography |
| MRI | Magnetic resonance imaging |
| MRI-PDFF | Magnetic resonance imaging proton density fat fraction |
| MRR | Mortality rate ratio |
| MRS | Magnetic resonance spectroscopy |
| NAFL | Nonalcoholic fatty liver |
| NAFLD | Nonalcoholic fatty liver disease |
| NAS | NAFLD Activity Score |
| NASH | Nonalcoholic steatohepatitis |
| NASH CRN, NASH-CRN | NASH Clinical Research Network |
| NATIVE | NASH Trial to Validate IVA337 Efficacy |
| NCHS | National Center for Health Statistics |
| NCQA | National Committee for Quality Assurance |
| NCT | National Clinical Trial (ClinicalTrials.gov identifier) |
| NDA | New Drug Application |
| NEJM | The New England Journal of Medicine |
| NHANES | National Health and Nutrition Examination Survey |
| NHW | Non-Hispanic White |
| NILDA, NILDAs | Noninvasive liver disease assessment |
| NIT, NITs | Noninvasive test |
| NJ | New Jersey |
| NMPA | National Medical Products Administration (China) |
| NT-proBNP | N-terminal pro b-type natriuretic peptide |
| NY | New York |
| NYHA | New York Heart Association |
| NYSE | New York Stock Exchange |
| OATP1B1/3 | Organic anion transporting polypeptide 1B1 and 1B3 |
| OCA | Obeticholic acid |
| OCT2 | Organic cation transporter 2 |
| OTC | Over-the-counter |
| OTCQX | OTCQX Best Market (United States over-the-counter market) |
| P | Placebo (LEGEND treatment arm) |
| P3NP | N-terminal procollagen III peptide |
| PA | Pennsylvania (PA Health and Wellness); prior authorization |
| pan-PPAR | Agonist of all three peroxisome proliferator-activated receptor isoforms |
| PCS | Physical component summary |
| PDFF | Proton density fat fraction |
| PDGF | Platelet-derived growth factor |
| PF | Physical functioning |
| PharmD | Doctor of Pharmacy |
| PIVENS | Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis (trial) |
| PK | Pharmacokinetic |
| PM | Person-months (as in /100PM, per 100 person-months) |
| PMPM | Per member per month |
| PNPLA3 | Patatin-like phospholipase domain-containing protein 3 |
| PP | Per protocol |
| PPAR, PPARs | Peroxisome proliferator-activated receptor |
| PPARα | Peroxisome proliferator-activated receptor alpha |
| PPARβ/δ, PPARδ | Peroxisome proliferator-activated receptor beta/delta |
| PPARγ | Peroxisome proliferator-activated receptor gamma |
| PPS | Per protocol set |
| PRIME | Priority Medicines (European Medicines Agency scheme) |
| Pro-C3 | N-terminal type III collagen propeptide |
| PRO, PROs | Patient-reported outcome |
| PTM | Placebo-matching tablets |
| PY | Person-years |
| Q1 | First quarter |
| Q4W | Every 4 weeks |
| QALY, QALYs | Quality-adjusted life year |
| QD | Once daily |
| QOL | Quality of life |
| QT | QT interval (electrocardiogram) |
| QTc | Corrected QT interval |
| RA | Receptor agonist |
| RCT, RCTs | Randomized controlled trial |
| Rd | Rate of insulin-stimulated muscle glucose disposal |
| RHHBY | Roche Holding AG OTCQX ticker symbol |
| RO, ROG | Roche Holding AG SIX Swiss Exchange ticker symbols |
| RR | Risk ratio |
| SAD | Single ascending doses |
| SAF | Steatosis-Activity-Fibrosis (scoring system) |
| SAF-A | SAF activity score |
| SAP | Statistical analysis plan |
| SAR | Saudi riyal |
| SAS | Safety analysis set |
| SAT | Subcutaneous adipose tissue |
| SC | Standard care |
| SD | Standard deviation |
| SE | Standard error |
| SF-36 | Medical Outcomes Study 36-Item Short-Form Health Survey |
| SF-6D | Short-Form 6-Dimension |
| SGLT-2i | Sodium-glucose cotransporter-2 inhibitors |
| SGLT2, SGLT-2 | Sodium-glucose cotransporter-2 |
| SHTG | Severe hypertriglyceridemia |
| SIX | SIX Swiss Exchange |
| SLD | Steatotic liver disease |
| SNP | Single nucleotide polymorphism |
| SOC, SoC | Standard of care |
| SPLENDOR | Surgical Procedures and Long-term Effectiveness in NASH Disease and Obesity Risk (cohort study) |
| SRTR | Scientific Registry of Transplant Recipients |
| SUCRA | Surface under the cumulative ranking curve |
| SUSAR | Suspected Unexpected Serious Adverse Reaction |
| T2D, T2DM | Type 2 diabetes; type 2 diabetes mellitus |
| T3 | Third tranche (of the Inventiva structured financing) |
| TAA | Thioacetamide |
| TE | Transient elastography |
| TEAE, TEAEs | Treatment-emergent adverse event |
| TG | Triglycerides |
| THR-α | Thyroid hormone receptor alpha |
| THR-β | Thyroid hormone receptor beta |
| TIMP-1 | Tissue inhibitor of metalloproteinase-1 |
| TM6SF2 | Transmembrane 6 superfamily member 2 |
| TW | Treatment week (TW4, TW12, TW24: treatment week 4, 12, 24) |
| TZDs | Thiazolidinediones |
| U/L | Units per liter |
| UGT, UGTs | Uridine 5'-diphospho-glucuronosyltransferase |
| UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7, UGT2B15, UGT2B17 | Uridine 5'-diphospho-glucuronosyltransferase isoforms |
| UK | United Kingdom |
| ULN | Upper limit of normal |
| US | United States |
| USA | United States of America |
| USD | United States dollars |
| V-1, V0, V1, V2, V3 | Study visits (V-1, screening visit; V0, randomization; V1 and V2, interim visits; V3, end of treatment visit) |
| VAT | Visceral adipose tissue |
| VCTE, VCTEs | Vibration-controlled transient elastography |
| VLDLs | Very-low-density lipoproteins |
| vs | Versus |
| Vz/F | Apparent volume of distribution |
| W24 | Week 24 |
| WAC | Wholesale acquisition cost |
| WHO | World Health Organization |
| WPAI:SHP | Work Productivity and Activity Impairment: Specific Health Problem |
| WSI | Whole slide image |
| WTP | Willingness to pay |
| α-SMA | Alpha-smooth muscle actin |

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
